Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000229350 | SCV000286121 | likely benign | Rhabdoid tumor predisposition syndrome 2 | 2024-01-19 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV000561612 | SCV000663961 | likely benign | Hereditary cancer-predisposing syndrome | 2015-11-11 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Sema4, |
RCV000561612 | SCV002535202 | likely benign | Hereditary cancer-predisposing syndrome | 2021-09-12 | criteria provided, single submitter | curation | |
Prevention |
RCV003919935 | SCV004732730 | likely benign | SMARCA4-related disorder | 2022-09-22 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |